Last reviewed · How we verify
NCT03261934
Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation
trial testing No intervention in Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation in 2,000 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | Beijing University of Chinese Medicine |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 January 2018 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across China |
Drugs / interventions tested
- No intervention
Conditions studied
- Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation — all drugs for Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation →
Sponsor
Beijing University of Chinese Medicine
Who can join
Adults 18 to 75, any sex, with Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic atrophic gastritis (CAG) is acknowledged as the precancerous stage of gastric cancer (GC). The present study aims to developed risk assessment and syndrome evolution models of CAG malignant transformation events combining TCM indicators with modern medicine indicators. The proposed study is a registry study based participant survey conducted in 4 hospitals in Beijing, China. After obtaining informed consent, a total of 2000 study patients diagnosed with CAG will be recruited. 10-year follow-ups are carried out on-site in hospitals and off-site by telephone to track malignant transformation events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03261934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other Beijing University of Chinese Medicine trials
Trials by the same sponsor.
- NCT06980636 — A Trial of Shengmai Liquid for Long COVID Fatigue. · Phase 4 · recruiting
- NCT07472777 — Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis · completed
- NCT05941598 — Electroacupuncture for Chemotherapy-Related Cognitive Impairment · Phase 2 · unknown
- NCT05508815 — Modified Zhiwang Decoction Combined With Methotrexate in the Treatment of Early Rheumatoid Arthritis · EARLY_PHASE1 · unknown
- NCT03759405 — IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03261934 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing University of Chinese Medicine
- Last refreshed: 29 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03261934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing